Skip to main content
Erschienen in: BMC Gastroenterology 1/2016

Open Access 01.12.2016 | Research article

Discounting the duration of bolus exposure in impedance testing underestimates acid reflux

verfasst von: Namasivayam Vikneswaran, Joseph A Murray

Erschienen in: BMC Gastroenterology | Ausgabe 1/2016

Abstract

Background

Combined impedance-pH testing (MII) allows for detection of reflux episodes regardless of pH. However impedance-based diagnosis of reflux may not routinely account for duration of the reflux episode. We hypothesize that impedance testing may be less sensitive than pH-testing in detecting acid reflux off therapy as a result of discounting duration of exposure.

Methods

Baseline characteristics and reflux parameters of MII studies performed off-anti-secretory medications were analyzed. Studies on acid suppressive medication and those with recording times less than 20 h or low baseline impedance were excluded.

Results

A total of 73 consecutive MII studies were analyzed of which 31 MII studies had elevated acid exposure while 16 were abnormal by impedance criteria. MII testing off-therapy was more likely to be abnormal by pH criteria (percent time pH < 4) than impedance criteria (total reflux):[42 vs 22 % (p =0.02)]. Acid exposure (percent time pH < 4) identified more studies as abnormal than MII-detected acid reflux episodes [42 vs 34 % (p < 0.01)]. Mean acid clearance time (pH-detected) was significantly longer than median bolus clearance time (impedance-detected) in the total [98.7 s vs 12.6 s (p < 0.01)], upright [58.6 s vs 13.1 s (p < 0.01)], and recumbent positions [136.7 s vs 14.2 s (p < 0.01)] with the greatest difference seen in the recumbent position. The mean ratio of mean acid clearance time (pH-detected) and the median bolus clearance time (impedance-detected) was significantly higher in the recumbent position compared to the upright position [11. vs 5.3 (p = 0.01)].

Conclusion

Ambulatory impedance testing underestimates acid reflux compared to esophageal acid exposure by discounting the prolonged period of mucosal contact with each acid reflux episode, particularly in the recumbent position.

Background

Current treatment paradigms for GERD are based on the objective demonstration of pathologic acid exposure by reflux testing or endoscopic evidence of mucosal disease [1]. Conventional ambulatory esophageal pH monitoring defines reflux as an abrupt drop in distal esophageal pH below 4 with pathological acid exposure defined by a composite of 6 variables of which acid exposure time (percentage time with pH <4) is the single most useful and reproducible index that correlates with disease severity and treatment response [24]. Combined impedance-pH testing (MII) offers a potentially more precise means of measuring reflux by allowing differentiation of reflux from swallow-induced pH changes that may result from consumption of foods and liquids with pH < 4 as well as identifying non-acid reflux [5, 6] .
However pathological reflux in MII studies is defined by the number of impedance-detected reflux events and their temporal association with symptoms and may not routinely account for the duration of the reflux episode [7, 8]. Furthermore software analysis can be set to only analyze reflux events that have detected by impedance, thereby ignoring those events that have been deemed to be reflux by pH characteristics alone.
The duration of esophageal acid exposure measured by pH has been previously demonstrated to be longer than bolus duration determined by impedance [7]. We hypothesize that impedance testing may be less sensitive than pH testing in detecting acid reflux as it discounts the duration of bolus exposure and that this effect may be particularly significant in the supine position and under-diagnose pathological reflux in those not on acid suppressing medications.

Methods

MII studies (Sandhill Scientific, Highlands Ranch, CO, USA) that were performed off-anti-secretory medications at Mayo Clinic, Rochester from 1 Jan 09 to 31 Mar 10 were retrospectively analyzed. MII studies were performed for the definitive diagnosis of pathological reflux in patients with refractory reflux symptoms, extra-esophageal reflux symptoms and for assessment prior to fundoplication. Ambulatory 24-h testing was performed after an overnight fast. The MII-pH catheter consists of a 2.1-mm polyurethane catheter incorporating 6 impedance segments and 1 pH-measuring electrode at 5 cm above the lower esophageal sphincter. Proton pump inhibitors and histamine-2 receptor antagonists were discontinued for 7 and 3 days prior to the test respectively. Patients undergoing testing are encouraged to maintain normal activities and sleep schedule. Post-test calibration of antimony pH probes is routinely performed to correct for pH drift [9]. Studies performed on acid suppressive medication, those with recording times less than 20 h and those with low baseline impedance reducing the sensitivity for detecting reflux events were excluded from analysis.
At the end of the 24 h recording period, data was transferred and analyzed manually using dedicated software (Bioview Analysis; Sandhill Scientific). All tracings were manually reviewed by the investigator [10]. Reflux events based on retrograde bolus events were initially identified by the analysis software and false positive events were deleted. Baseline characteristics as well as reflux testing parameters were analyzed including the following parameters - (1) the percentage of total time that the pH was < 4, (2) the percentage of upright time that the pH was <4, (3) the percentage of supine time that the pH was < 4, (4) the number of reflux events, (5) the number of reflux events longer than 5 min, and (6) the longest reflux event, (7) total number of impedance-detected reflux episodes (8) impedance-detected reflux episodes in the recumbent position (9) impedance-detected reflux episodes in the supine position. pH indices were compared with the corresponding impedance indices in the total, upright and recumbent positions. In particular, the reflux clearance characteristics were analyzed by comparing the mean acid clearance time (pH-detected) with the median bolus clearance time (impedance-detected) in the total, upright and recumbent position. The ratio of the mean acid clearance time (pH-detected) and the median bolus clearance time (impedance-detected) was analyzed in the upright and recumbent position to compare the magnitude of the discrepancy between pH and impedance in the upright and recumbent positions.
Distal esophageal acid exposure can be quantified using the percentage time pH < 4 or DeMeester score. MII studies were categorized as abnormal by acid exposure criteria if the percentage of total time that the pH was < 4 was 4.2 % or more [11]. MII studies were categorized as abnormal by impedance criteria if they had elevated number of impedance-detected reflux episodes (73 or more) [7]. The proportion of MII that were positive by impedance criteria was compared to the proportion of MII that were positive by acid exposure. In addition, the MII studies were separately categorized by acid exposure criteria on the basis of an elevated DeMeester score (14.7 or more) and the proportion of abnormal studies were compared with the proportion of abnormal MII by impedance criteria [11].
Baseline continuous data was compared using the 2-sample t test or the Wilcoxon rank-sum test depending on the data normality. Baseline categoric data was compared using the chi-squared test. Statistical analysis was performed using SPSS software (Statistical Package for the Social Sciences, Chicago, Illnois, USA). Statistical significance was defined as p value <0.05. This study was approved by Mayo Clinic Institutional Review Board. The waiver of the requirement to obtain informed consent was approved in accordance with 45 CFR 46.116.

Results

A total of 73 consecutive MII studies performed off anti-secretory medication were analyzed. Of these, 50 were performed in females and the median age was 50 years (range 25–78). Baseline MII results are shown (Table 1). Thirty one MII studies had elevated acid exposure while 16 were abnormal by impedance criteria.
Table 1
Baseline MII results
 
Parameters
Median
Range (Min, Max)
Duration of analysis
Duration of analysis total (hours:min)
21:22
(20:01, 24:22)
Duration of analysis upright (hours:min)
12:17
(2:35, 18:25)
Duration of analysis recumbent (hours:min)
8:59
(2:50, 20:47)
Median gastric pH
2.2
(1.6,3.7)a
Esophageal acid exposure
Percentage time total ph < 4 (%)
1.6
(0,17.3)
Percentage time upright ph < 4 (%)
1.9
(0,24.4)
Percentage time recumbent ph < 4 (%)
0.8
(0,23.3)
Episodes Over 5 min
0.0
(0,11.1)
Longest Episode/min
4.8
(1,96.5)
Total Episodes
27.2
(1.1, 122.7)
Demeester score
5.8
(0.8,59.1)
Impedance
Baseline impedance/Ω
1614
(588,5420)
no. of impedance events (total)
41
(6,162)
no. of impedance events (upright)
37
(2,149)
no. of impedance events (recumbent)
5
(0,45)
longest impedance detected episode/min
3.4
(0.2,161)
Acid reflux
21
(0,88)
Non-acid reflux
17
(1,159)
 
Bolus exposure (%)
1.3
(0.1, 21.2)
aGastric pH data missing in 27 studies
Fifteen and thirty one studies had elevated acid exposure in the upright and recumbent position respectively. Fifteen and thirty one studies had increased impedance-detected reflux events in the upright and recumbent position respectively.
MII testing off-therapy was more likely to be abnormal by pH criteria (percent time pH < 4) than impedance criteria (total reflux):42 vs 22 % (p =0.02). Acid exposure (percent time pH < 4) identified more abnormal studies than MII detected reflux episodes: 42 vs 34 % (p <0.01).
Testing off therapy was more likely to be abnormal by DeMeester score than impedance criteria (total reflux): 41.1 vs 21.9 % (p = 0.01). The median longest episode detected by pH was significantly longer than the longest episode detected by impedance: 4.8 (0.1, 96.5) vs 3.4 (0.2, 161.4) minutes (p <0.01). The median total episodes of reflux detected by pH was significantly fewer than impedance-detected reflux episodes: 27.2 (1.1, 122.7) vs 41 (6,162) p < 0.01.
We further analyzed the reflux clearance characteristics by comparing pH versus impedance (Table 2). The mean acid clearance time (pH-detected) was significantly longer than the median bolus clearance time (impedance-detected) in the total, upright and recumbent positions: 98.7 s vs 12.6 s (p < 0.01), 58.6 s vs 13.1 s (p < 0.01), 136.7 s vs 14.2 s (p < 0.01) with the greatest difference seen in the recumbent position. The mean ratio of mean acid clearance time (pH-detected) and the median bolus clearance time (impedance-detected) was significantly higher in the recumbent position compared to the upright position: 11. vs 5.3 (p = 0.01). This indicates that the difference between pH detected acid clearance and impedance-detected bolus clearance is greater in the recumbent position compared to the upright position.
Table 2
Temporal characteristics of acid clearance versus impedance detected bolus clearance
 
Parameters
Median
Range (Min, Max)
Esophageal acid exposure
Mean Acid Clearance time - total (sec)
66
(7,1257)
Mean Acid Clearance time - upright (sec)
48
(0,179)
Mean Acid Clearance time - recumbent (sec)
44
(0,1257)
Impedance
Median Bolus Clearance Time-total/sec
12
(3,31)
Median Bolus Clearance Time-upright/sec
12
(5,37)
Median Bolus Clearance Time- recumbent/sec
10
(0,96)

Discussion

Standard pH- only ambulatory esophageal monitoring has been largely replaced with combined impedance-pH monitoring on the premise that impedance provides a diagnostic gain by detecting non-acid reflux and improving symptom reflux correlation during testing on therapy [1214]. Impedance monitoring has expanded on pH-metry with detection of reflux of liquid irrespective of acidity and gas which has enabled detection of reflux on anti-secretory therapy as well as characterization of non-reflux conditions such as rumination and supragastric belching [15, 16].
However, impedance-based categorization of reflux based on normative data has not been validated by outcome-based studies and recent outcome-based studies suggest impedance parameters may not be as predictive as conventional acid exposure in predicting treatment response [17, 18]. The true relevance of negative impedance studies performed on antisecretory therapy without prior confirmation of reflux is also unclear.
Our study demonstrates that in testing off therapy, impedance underestimates reflux compared to esophageal acid exposure resulting in a decreased proportion of studies positive for pathological reflux. Both acid exposure (pH <4) as well as DeMeester score were more likely to result in a positive test than impedance detected reflux episodes. This is despite the increased detection of reflux episodes by impedance compared to conventional pH criteria.
This may be due to the failure of impedance to account for the prolonged period of mucosal contact with each acid reflux episode particularly in the recumbent position. The mean acid clearance time (pH-detected) was significantly longer than the median bolus clearance time (impedance-detected) in all positions. Furthermore, the median longest episode was significantly longer with pH testing compared to impedance. These findings indicate that impedance underestimates the duration of bolus exposure to esophageal mucosa compared to pH. These differences are more marked in the recumbent position since the ratio of pH detected mean acid clearance time and impedance detected median bolus clearance time was significantly higher in the recumbent position compared to the upright position.
These findings are consistent with the two-step acid clearing mechanism. Esophageal acid clearance is initiated by peristalsis and completed following neutralization by swallowed alkaline saliva. Impedance returns to baseline values with clearance of the majority of the acid bolus by peristalsis but pH detects the small amount of residual acid that persists until neutralization by alkaline saliva [19]. This difference is more marked in the recumbent period where the much longer acid reflux events are not adequately reflected by the impedance measures. This is likely due to the lack of buffering by alkaline saliva as the production of saliva is reduced at night. Decreased swallowing frequency, salivary production and decreased delivery to the distal esophagus during sleep retards neutralization of esophageal pH after acid reflux [20]. So, the pH does not normalize as quickly due to the decreased saliva even though bolus clearance by impedance is almost equal in the upright and recumbent position as demonstrated in this study. Hence in studies performed off medication, the pH component appears to be more reliable particularly in the recumbent position. Studies with low baseline impedance that could confound analysis by lowering the sensitivity of impedance detection of reflux were excluded hence this could not account for the results.
Nocturnal acid reflux can induce sleep disturbances and decrease health-related quality of life [21, 22]. Furthermore nocturnal acid reflux has been associated with more severe esophageal mucosal damage, such as peptic stricture and adenocarcinoma and an increased risk of pulmonary complications [23, 24]. Under-diagnosis of reflux may have significant public health implications.
In the absence of acid suppression, clinicians need to pay more attention to pH parameters than impedance. Perhaps impedance-based diagnostic criteria need to be revised to accurately reflect duration of acid contact especially in the recumbent position. Current analysis software may calculate impedance-detected bolus exposure. Although normative data on impedance-derived bolus measures is available and could potentially be incorporated into impedance-based diagnosis of reflux, emerging studies suggest that impedance parameters may not be as predictive as conventional acid exposure in predicting treatment response [17, 18]. Future studies could compare pH- and impedance-detected bolus exposure to assess the impact of incorporating impedance-detected bolus exposure on the impedance-based diagnosis of reflux.
The findings may have implications for testing on therapy that merit further study. Patients with prolonged non-acid reflux events below the current impedance-based diagnostic thresholds may still have clinically significant reflux events that could account for symptoms even if they may not be as injurious to the mucosa.
There are shortcomings to this study. This is a retrospective review. Recumbency was also assumed to be a surrogate for sleep when saliva production in decreased though differences in reflux characteristics of recumbent-awake and recumbent-asleep periods are not routinely measured in clinical practice [25].

Conclusion

In conclusion, impedance underestimates acid reflux compared to esophageal acid exposure with testing off therapy. This may be due to the failure of impedance to account for the prolonged period of mucosal contact with each acid reflux episode particularly in the recumbent position. Clinicians should continue to rely on standard pH parameters for assessment of reflux in those patients being studied off acid suppressive medications.

Abbreviations

MII, Combined impedance-pH testing

Acknowledgements

Not applicable.

Funding

Not applicable.

Availability of data and materials

The data will not be made available in order to protect the participants’ identity.

Authors’ contributions

VN: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis. JAM: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis; study supervision. VN is the guarantor of the submission. Both authors read and approved the final version of the manuscript.

Authors’ information

VN
Senior Consultant
Department of Gastroenterology and Hepatology
Singapore General Hospital
JAM
Professor of Medicine
Division of Gastroenterology and Hepatology and Department of Immunology
Mayo Clinic
Rochester, MN 55905

Competing interests

The authors declare that they have no competing interest.
Not applicable.
This study was approved by Mayo Clinic Institutional Review Board. The waiver of the requirement to obtain informed consent was approved in accordance with 45 CFR 46.116.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383–91. 91 e1-5.CrossRefPubMed Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383–91. 91 e1-5.CrossRefPubMed
2.
Zurück zum Zitat Johnson LF, DeMeester TR. Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol. 1986;8 Suppl 1:52–8.CrossRefPubMed Johnson LF, DeMeester TR. Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol. 1986;8 Suppl 1:52–8.CrossRefPubMed
3.
Zurück zum Zitat Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996;111:1192–9.CrossRefPubMed Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996;111:1192–9.CrossRefPubMed
4.
Zurück zum Zitat Khajanchee YS, Hong D, Hansen PD, Swanstrom LL. Outcomes of antireflux surgery in patients with normal preoperative 24-hour pH test results. Am J Surg. 2004;187:599–603.CrossRefPubMed Khajanchee YS, Hong D, Hansen PD, Swanstrom LL. Outcomes of antireflux surgery in patients with normal preoperative 24-hour pH test results. Am J Surg. 2004;187:599–603.CrossRefPubMed
5.
Zurück zum Zitat Hila A, Agrawal A, Castell DO. Combined multichannel intraluminal impedance and pH esophageal testing compared to pH alone for diagnosing both acid and weakly acidic gastroesophageal reflux. Clin Gastroenterol Hepatol. 2007;5:172–7.CrossRefPubMed Hila A, Agrawal A, Castell DO. Combined multichannel intraluminal impedance and pH esophageal testing compared to pH alone for diagnosing both acid and weakly acidic gastroesophageal reflux. Clin Gastroenterol Hepatol. 2007;5:172–7.CrossRefPubMed
6.
7.
Zurück zum Zitat Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol. 2004;99:1037–43.CrossRefPubMed Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol. 2004;99:1037–43.CrossRefPubMed
8.
Zurück zum Zitat Zentilin P, Iiritano E, Dulbecco P, et al. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Dig Liver Dis. 2006;38:226–32.CrossRefPubMed Zentilin P, Iiritano E, Dulbecco P, et al. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Dig Liver Dis. 2006;38:226–32.CrossRefPubMed
9.
Zurück zum Zitat Wise JL, Kammer PK, Murray JA. Post-test calibration of single-use, antimony, 24-hour ambulatory esophageal pH probes is necessary. Dig Dis Sci. 2004;49:688–92.CrossRefPubMed Wise JL, Kammer PK, Murray JA. Post-test calibration of single-use, antimony, 24-hour ambulatory esophageal pH probes is necessary. Dig Dis Sci. 2004;49:688–92.CrossRefPubMed
10.
Zurück zum Zitat Ravi K, DeVault KR, Murray JA, Bouras EP, Francis DL. Inter-observer agreement for multichannel intraluminal impedance-pH testing. Dis Esophagus. 2010;23:540–4.CrossRefPubMed Ravi K, DeVault KR, Murray JA, Bouras EP, Francis DL. Inter-observer agreement for multichannel intraluminal impedance-pH testing. Dis Esophagus. 2010;23:540–4.CrossRefPubMed
11.
Zurück zum Zitat Johnson LF, Demeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol. 1974;62:325–32.PubMed Johnson LF, Demeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol. 1974;62:325–32.PubMed
12.
Zurück zum Zitat Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120:1599–606.CrossRefPubMed Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120:1599–606.CrossRefPubMed
13.
Zurück zum Zitat Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol. 2006;101:1956–63.CrossRefPubMed Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol. 2006;101:1956–63.CrossRefPubMed
14.
Zurück zum Zitat Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2010;32:334–43.CrossRefPubMed Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2010;32:334–43.CrossRefPubMed
15.
16.
Zurück zum Zitat Saleh CM, Bredenoord AJ. Utilization of esophageal function testing for the diagnosis of the rumination syndrome and belching disorders. Gastrointest Endosc Clin N Am. 2014;24:633–42.CrossRefPubMed Saleh CM, Bredenoord AJ. Utilization of esophageal function testing for the diagnosis of the rumination syndrome and belching disorders. Gastrointest Endosc Clin N Am. 2014;24:633–42.CrossRefPubMed
17.
Zurück zum Zitat Patel A, Sayuk GS, Gyawali CP. Acid-based parameters on pH-impedance testing predict symptom improvement with medical management better than impedance parameters. Am J Gastroenterol. 2014;109:836–44.CrossRefPubMedPubMedCentral Patel A, Sayuk GS, Gyawali CP. Acid-based parameters on pH-impedance testing predict symptom improvement with medical management better than impedance parameters. Am J Gastroenterol. 2014;109:836–44.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Patel A, Sayuk GS, Gyawali CP. Parameters on esophageal pH-impedance monitoring that predict outcomes of patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2015;13:884–91.CrossRefPubMed Patel A, Sayuk GS, Gyawali CP. Parameters on esophageal pH-impedance monitoring that predict outcomes of patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2015;13:884–91.CrossRefPubMed
19.
Zurück zum Zitat Helm JF, Dodds WJ, Pelc LR, Palmer DW, Hogan WJ, Teeter BC. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med. 1984;310:284–8.CrossRefPubMed Helm JF, Dodds WJ, Pelc LR, Palmer DW, Hogan WJ, Teeter BC. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med. 1984;310:284–8.CrossRefPubMed
20.
Zurück zum Zitat Orr WC, Johnson LF. Responses to different levels of esophageal acidification during waking and sleep. Dig Dis Sci. 1998;43:241–5.CrossRefPubMed Orr WC, Johnson LF. Responses to different levels of esophageal acidification during waking and sleep. Dig Dis Sci. 1998;43:241–5.CrossRefPubMed
21.
Zurück zum Zitat Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98:1487–93.CrossRefPubMed Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98:1487–93.CrossRefPubMed
22.
Zurück zum Zitat Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001;161:45–52.CrossRefPubMed Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001;161:45–52.CrossRefPubMed
23.
Zurück zum Zitat Orr WC, Allen ML, Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol. 1994;89:509–12.PubMed Orr WC, Allen ML, Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol. 1994;89:509–12.PubMed
24.
Zurück zum Zitat Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.CrossRefPubMed Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.CrossRefPubMed
25.
Zurück zum Zitat Poh CH, Gasiorowska A, Allen L, et al. Reassessment of the principal characteristics of gastroesophageal reflux during the recumbent period using integrated actigraphy-acquired information. Am J Gastroenterol. 2010;105:1024–31.CrossRefPubMed Poh CH, Gasiorowska A, Allen L, et al. Reassessment of the principal characteristics of gastroesophageal reflux during the recumbent period using integrated actigraphy-acquired information. Am J Gastroenterol. 2010;105:1024–31.CrossRefPubMed
Metadaten
Titel
Discounting the duration of bolus exposure in impedance testing underestimates acid reflux
verfasst von
Namasivayam Vikneswaran
Joseph A Murray
Publikationsdatum
01.12.2016
Verlag
BioMed Central
Erschienen in
BMC Gastroenterology / Ausgabe 1/2016
Elektronische ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-016-0471-y

Weitere Artikel der Ausgabe 1/2016

BMC Gastroenterology 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.